| Half-life | 30 hours |
| Tmax | 7 h |
| Bioavailability | 65 % (approx) |
| Protein Binding | 93 % |
| Volume of Distribution | 20 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Less anticholinergic than amitriptyline; better tolerated in elderly but still caution due to cardiac conduction effects. |
Severity: Moderate
Adverse Effects:
Dry mouth, constipation, arrhythmia risk, dizziness, sedation
Contraindications:
Concurrent MAOI use, recent MI
Precautions:
Monitor ECG if cardiac disease; start low dose; avoid abrupt discontinuation.